日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Review of Existing Approaches and Potential Role of Pharmacometrics in the Interpretation of Prognostic Circulating Serum Biomarkers in Advanced NSCLC

现有方法综述及药代动力学在晚期非小细胞肺癌预后循环血清生物标志物解读中的潜在作用

Ojara, Francis Williams; Nassar, Yomna M; Geiger, Kimberly; van Dyk, Madele; Holdenrieder, Stefan; Joerger, Markus; Kloft, Charlotte

Author Correction: Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours

作者更正:中和 GDF-15 可以克服实体瘤中的抗 PD-1 和抗 PD-L1 耐药性

Melero, Ignacio; de Miguel Luken, Maria; de Velasco, Guillermo; Garralda, Elena; Martín-Liberal, Juan; Joerger, Markus; Alonso, Guzman; Goebeler, Maria-Elisabeth; Schuler, Martin; König, David; Dummer, Reinhard; Reig, Maria; Rodriguez Ruiz, Maria-Esperanza; Calvo, Emiliano; Esteban-Villarrubia, Jorge; Oberoi, Arjun; Sabat, Paula; Soto-Castillo, Juan José; Koster, Kira-Lee; Saavedra, Omar; Sayehli, Cyrus; Gromke, Tanja; Läubli, Heinz; Ramelyte, Egle; Fortuny, Marta; Landa-Magdalena, Ana; Moreno, Irene; Torres-Jiménez, Javier; Hernando-Calvo, Alberto; Hess, Dagmar; Racca, Fabricio; Richly, Heike; Schmitt, Andreas M; Eggenschwiler, Corinne; Sanduzzi-Zamparelli, Marco; Vilalta-Lacarra, Anna; Trojan, Jörg; Koch, Christine; Galle, Peter R; Foerster, Friedrich; Trajanoski, Zlatko; Hackl, Hubert; Gogolla, Falk; Koll, Florestan J; Wild, Peter; Chun, Felix Kyoung Hwan; Reis, Henning; Lloyd, Peter; Machacek, Matthias; Gajewski, Thomas F; Fridman, Wolf H; Eggermont, Alexander M M; Bargou, Ralf; Schöniger, Sandra; Rüschoff, Josef; Tereshchenko, Anastasiia; Zink, Carina; da Silva, Antonio; Lichtenegger, Felix S; Akdemir, Julia; Rüdiger, Manfred; L'Huillier, Phil; Dutta, Aradhana; Haake, Markus; Auckenthaler, Alexandra; Gjorgjioska, Ana; Rössler, Bernhard; Hermann, Frank; Liebig, Mara; Reichhardt, Daniela; Schuberth-Wagner, Christine; Wischhusen, Jörg; Fettes, Petra; Auer, Marlene; Klar, Kathrin; Leo, Eugen

Overall survival of recurrent/metastatic head & neck squamous cell carcinoma patients progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy: results of SAKK 11/16, a phase IIa trial.

接受至少 1 线系统治疗后进展的复发/转移性头颈部鳞状细胞癌患者的总体生存率,采用新型的、首创的基于细胞封装的免疫疗法 MVX-ONCO-1 进行治疗:SAKK 11/16 IIa 期试验的结果

Fernandez Eugenio, Vernet Rémi, Urwyler Muriel, Von Rohr Olivier, Charrier Emily, Belkouch Marie-Claude, Saingier Valentin, Courtout Fabien, DeVito Claudio, Ancrenaz Virginie, Dulguerov Nicolas, Karenovics Wolfram, Grogg Julien, Renaux Jessica, Gobat Katrin, Müller Gisela, Brezina Tomas, Rordorf Tamara, Joerger Markus, Michielin Olivier, Villard Jean, Mach Nicolas

Adjuvant Aspirin Treatment in PIK3CA-Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial

PIK3CA突变结肠癌患者的阿司匹林辅助治疗:SAKK 41/13前瞻性随机安慰剂对照双盲试验

Güller, Ulrich; Hayoz, Stefanie; Horber, Daniel; Jochum, Wolfram; De Dosso, Sara; Koeberle, Dieter; Schacher, Sabina; Inauen, Roman; Stahl, Michael; Delaunoit, Thierry; Ettrich, Thomas; Bodoky, György; Michel, Pierre; Koessler, Thibaud; Rothgiesser, Karin; Calmonte, Sandra; Joerger, Markus

Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendations

紫杉醇治疗药物监测——国际治疗药物监测和临床毒理学协会的建议

Hertz, Daniel L; Joerger, Markus; Bang, Yung-Jue; Mathijssen, Ron H; Zhou, Caicun; Zhang, Li; Gandara, David; Stahl, Michael; Monk, Bradley J; Jaehde, Ulrich; Beumer, Jan H

Combination Therapy with Immune Checkpoint Inhibitors and Histone Deacetylase Inhibitors or Alkylating Agents

免疫检查点抑制剂与组蛋白去乙酰化酶抑制剂或烷化剂的联合治疗

Joerger, Markus; Koster, Kira-Lee; Janik, Tomas; de Jong, Floris A

Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trial

TLD-1(一种新型脂质体阿霉素)在 I 期试验中的群体药代动力学研究

Mc Laughlin, Anna M; Hess, Dagmar; Michelet, Robin; Colombo, Ilaria; Haefliger, Simon; Bastian, Sara; Rabaglio, Manuela; Schwitter, Michael; Fischer, Stefanie; Eckhardt, Katrin; Hayoz, Stefanie; Kopp, Christoph; Klose, Marian; Sessa, Cristiana; Stathis, Anastasios; Halbherr, Stefan; Huisinga, Wilhelm; Joerger, Markus; Kloft, Charlotte

Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors

一项I/Ib期、开放标签、多中心、剂量递增研究,旨在评估抗TGF-β单克隆抗体NIS793联合spartalizumab治疗晚期肿瘤成年患者的疗效。

Bauer, Todd M; Santoro, Armando; Lin, Chia-Chi; Garrido-Laguna, Ignacio; Joerger, Markus; Greil, Richard; Spreafico, Anna; Yau, Thomas; Goebeler, Maria-Elisabeth; Hütter-Krönke, Marie Luise; Perotti, Antonella; Juif, Pierre-Eric; Lu, Darlene; Barys, Louise; Cremasco, Viviana; Pelletier, Marc; Evans, Helen; Fabre, Claire; Doi, Toshikiko

Non-pharmaceutical interventions to optimize cancer immunotherapy

优化癌症免疫疗法的非药物干预措施

Boesch, Maximilian; Baty, Florent; Rassouli, Frank; Kowatsch, Tobias; Joerger, Markus; Früh, Martin; Brutsche, Martin H

C-Reactive Protein as an Early Predictor of Efficacy in Advanced Non-Small-Cell Lung Cancer Patients: A Tumor Dynamics-Biomarker Modeling Framework

C反应蛋白作为晚期非小细胞肺癌患者疗效的早期预测因子:肿瘤动力学-生物标志物建模框架

Nassar, Yomna M; Ojara, Francis Williams; Pérez-Pitarch, Alejandro; Geiger, Kimberly; Huisinga, Wilhelm; Hartung, Niklas; Michelet, Robin; Holdenrieder, Stefan; Joerger, Markus; Kloft, Charlotte